Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma

References

• Jain N. Evolving treatment paradigm in frontline CLL. J Clin Oncol Oncol Pract. 2021;18(2):114–115.
   Google Scholar
• Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):69. doi: 10.1186/s13045-021-01054-w.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves venetoclax for CLL and SLL. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll
   Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi: 10.1056/NEJMoa1815281.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200. doi: 10.1016/S1470-2045(20)30443-5.
   PubMed Web of Science ®Google Scholar
• Sury K. Update on the prevention and treatment of tumor lysis syndrome. Journal of Onco-Nephrology. 2019;3(1):19–30. doi: 10.1177/2399369319837212.
   Google Scholar
• Rogers KA, Lu X, Emond B, et al. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a real-world US retrospective study. J Manag Care Spec Pharm. 2022;28(9):1033–1045. doi: 10.18553/jmcp.2022.22075.
   PubMed Web of Science ®Google Scholar
• Brem EA, O'Brien S. Frontline management of CLL in 2021. J Clin Oncol Oncol Pract. 2021;18(2):109–113.
   Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–2103. doi: 10.1056/NEJMoa1900574.
   PubMed Web of Science ®Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. 2022;1(7):1–13. doi: 10.1056/EVIDoa2200006.
   Google Scholar
• Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853–3865. doi: 10.1200/JCO.21.00807.
   PubMed Web of Science ®Google Scholar
• Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. 2020. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2020. doi: 10.48550/arXiv.2001.09765.
   Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron Health, SEER, and NPCR. medRxiv. 2020. doi: 10.1101/2020.03.16.20037143.
   Google Scholar
• Venclexta (venetoclax tablets) Prescribing Information. North Chicago, IL, 2022.
   Google Scholar
• Rogers KA, Emond B, Manceur AM, et al. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. Curr Med Res Opin. 2021 Aug;37(8):1409–1420. doi: 10.1080/03007995.2021.1929894.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi: 10.1093/aje/kwq433.
   PubMed Web of Science ®Google Scholar
• Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006;3(8):438–447. doi: 10.1038/ncponc0581.
   PubMedGoogle Scholar
• Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020;7(2):e168–e176. doi: 10.1016/S2352-3026(19)30253-4.
   PubMed Web of Science ®Google Scholar
• Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–1517.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25(14):4264–4270. doi: 10.1158/1078-0432.CCR-19-0361.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi: 10.1056/NEJMoa1509388.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Miranda P, Roos J, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Leuk Lymphoma. 2020;395(10232):1–10. doi: 10.1016/S0140-6736(20)30262-2.
   Google Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. doi: 10.1016/S1470-2045(22)00293-5.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Tedeschi A. Chemo-immunotherapy for older patients with chronic lymphocytic leukemia - time to retire? Hemasphere. 2019;3(4):e278. doi: 10.1097/HS9.0000000000000278.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87. doi: 10.1001/jamaoncol.2014.218.
   PubMed Web of Science ®Google Scholar
• Mato AR, Samp JC, Gauthier G, et al. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. Cancer Biol Ther. 2018;19(7):636–643. doi: 10.1080/15384047.2018.1449616.
   PubMed Web of Science ®Google Scholar
• Gazyva (obinutuzumab) Prescribing Information. South San Francisco, CA: genentech, Inc. 2022.
   Google Scholar
• Snowden A, Hayden I, Dixon J, et al. Prevention and management of obinutuzumab-associated toxicities: australian experience. Int J Nurs Pract. 2015;21(Suppl 3):15–27. doi: 10.1111/ijn.12412.
   PubMedGoogle Scholar
• Bewarder M, Stilgenbauer S, Thurner L, et al. Current treatment options in CLL. Cancers (Basel). 2021;13(10):2468. doi: 10.3390/cancers13102468.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020;2020(1):357–362. doi: 10.1182/hematology.2020000120.
   PubMedGoogle Scholar
• Kater AP, Slinger E, Cretenet G, et al. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021;5(23):5410–5414. doi: 10.1182/bloodadvances.2021004861.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi: 10.1056/NEJMoa1215637.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Byrd JC, O'Brien S, et al. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019;186(1):184–188. doi: 10.1111/bjh.15791.
   PubMed Web of Science ®Google Scholar